Related references
Note: Only part of the references are listed.Pathogenesis beyond the cancer clone(s) in multiple myeloma
Giada Bianchi et al.
BLOOD (2015)
Association of Antigen-Specific T-cell Responses with Antigen Expression and Immunoparalysis in Multiple Myeloma
Sabrina Fichtner et al.
CLINICAL CANCER RESEARCH (2015)
Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells
A. Ray et al.
LEUKEMIA (2015)
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Multiple myeloma induces Mcl-1 expression and survival of myeloid-derived suppressor cells
Kim De Veirman et al.
Oncotarget (2015)
A multiepitope of XBP1, CD138 and CS1 peptides induces myeloma-specific cytotoxic T lymphocytes in T cells of smoldering myeloma patients
J. Bae et al.
LEUKEMIA (2015)
FOXP3 and CTLA4 overexpression in multiple myeloma bone marrow as a sign of accumulation of CD4+ T regulatory cells
Walter Moises Tobias Braga et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies
Shannon L. Maude et al.
CANCER JOURNAL (2014)
Combination Immunotherapy after ASCT for Multiple Myeloma Using MAGE-A3/Poly-ICLC Immunizations Followed by Adoptive Transfer of Vaccine-Primed and Costimulated Autologous T Cells
Aaron P. Rapoport et al.
CLINICAL CANCER RESEARCH (2014)
Daratumumab granted breakthrough drug status
Jacob P. Laubach et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2014)
Immune Checkpoint Blockade
Jarushka Naidoo et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2014)
Phage idiotype vaccination: first phase I/II clinical trial in patients with multiple myeloma
Tim Roehnisch et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2014)
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
Caroline Robert et al.
LANCET (2014)
Cancer-Testis Antigen 7 Expression and Immune Responses Following Allogeneic Stem Cell Transplantation for Multiple Myeloma
Eleanor M. Tyler et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma
Jedd D. Wolchok et al.
PHARMACEUTICAL SCIENCE TO IMPROVE THE HUMAN CONDITION: PRIX GALIEN USA 2012 (2013)
WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T cell-depleted hematopoietic stem cell transplantation and donor lymphocyte infusions
Eleanor M. Tyler et al.
BLOOD (2013)
Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC
Shauna M. Collins et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Vaccination with Dendritic Cell/Tumor Fusions following Autologous Stem Cell Transplant Induces Immunologic and Clinical Responses in Multiple Myeloma Patients
Jacalyn Rosenblatt et al.
CLINICAL CANCER RESEARCH (2013)
Enhanced cross-priming of naive CD8+ T cells by dendritic cells treated by the IMiDs® immunomodulatory compounds lenalidomide and pomalidomide
Jake Y. Henry et al.
IMMUNOLOGY (2013)
Safety, Efficacy, and Biomarkers of Nivolumab With Vaccine in Ipilimumab-Refractory or -Naive Melanoma
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Biological functions of ecto-enzymes in regulating extracellular adenosine levels in neoplastic and inflammatory disease states
Maria Serena Longhi et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2013)
Microenvironmental regulation of tumor progression and metastasis
Daniela F. Quail et al.
NATURE MEDICINE (2013)
Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma
Omid Hamid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia
Stephan A. Grupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Enhancement of Tumor-Reactive Cytotoxic CD4+ T-cell Responses after Ipilimumab Treatment in Four Advanced Melanoma Patients
Shigehisa Kitano et al.
CANCER IMMUNOLOGY RESEARCH (2013)
A CD38/CD203a/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes
Alberto L. Horenstein et al.
ONCOIMMUNOLOGY (2013)
A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma
Jeffrey A. Zonder et al.
BLOOD (2012)
Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study
Henk M. Lokhorst et al.
BLOOD (2012)
A novel immunogenic CS1-specific peptide inducing antigen-specific cytotoxic T lymphocytes targeting multiple myeloma
Jooeun Bae et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Targeting Multiple-Myeloma-Induced Immune Dysfunction to Improve Immunotherapy Outcomes
Sergio Rutella et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2012)
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
Suzanne L. Topalian et al.
CURRENT OPINION IN IMMUNOLOGY (2012)
Cyclic ADP-ribose and Nicotinic Acid Adenine Dinucleotide Phosphate (NAADP) as Messengers for Calcium Mobilization
Hon Cheung Lee
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Phase I Trial of Anti-CS1 Monoclonal Antibody Elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma
Andrzej J. Jakubowiak et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
Sagar Lonial et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Ipilimumab Increases Activated T Cells and Enhances Humoral Immunity in Patients With Advanced Melanoma
Jeffrey S. Weber et al.
JOURNAL OF IMMUNOTHERAPY (2012)
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma
Aaron P. Rapoport et al.
BLOOD (2011)
Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma
Jacalyn Rosenblatt et al.
BLOOD (2011)
Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma
Luisa Giaccone et al.
BLOOD (2011)
Pitfalls of vaccinations with WT1-, Proteinase3-and MUC1-derived peptides in combination with MontanideISA51 and CpG7909
Juergen Kuball et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
Michel de Weers et al.
JOURNAL OF IMMUNOLOGY (2011)
PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-cell Responses to Autologous Dendritic Cell/Myeloma Fusion Vaccine
Jacalyn Rosenblatt et al.
JOURNAL OF IMMUNOTHERAPY (2011)
Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia
David L. Porter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
Don M. Benson et al.
BLOOD (2010)
Tumor Antigen-Targeted, Monoclonal Antibody-Based Immunotherapy: Clinical Response, Cellular Immunity, and Immunoescape
Robert L. Ferris et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Idiotype-pulsed antigen presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival
Martha Q. Lacy et al.
AMERICAN JOURNAL OF HEMATOLOGY (2009)
Functional Interaction of Plasmacytoid Dendritic Cells with Multiple Myeloma Cells: A Therapeutic Target
Dharminder Chauhan et al.
CANCER CELL (2009)
Phase I Study of Ipilimumab, an Anti-CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma
Stephen M. Ansell et al.
CLINICAL CANCER RESEARCH (2009)
Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma
Frits van Rhee et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Proteasome inhibitors in the treatment of multiple myeloma
J. J. Shah et al.
LEUKEMIA (2009)
Myeloid-derived suppressor cells as regulators of the immune system
Dmitry I. Gabrilovich et al.
NATURE REVIEWS IMMUNOLOGY (2009)
A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma
Laura Rosinol et al.
BLOOD (2008)
MAGE-C1/CT7 is the dominant cancer-testis antigen targeted by humoral immune responses in patients with multiple myeloma
A. Curioni-Fontecedro et al.
LEUKEMIA (2008)
Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma
John Kuruvilla et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2007)
Tremelimumab (CP-675,206), a cytotoxic T lymphocyte-associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer
Antoni Ribas et al.
ONCOLOGIST (2007)
Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-γ and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway
Jizhong Liu et al.
BLOOD (2007)
Reduced-intensity conditioning for myeloma:: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning
Charles Crawley et al.
BLOOD (2007)
A comparison of allografting with autografting for newly diagnosed myeloma
Benedetto Bruno et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Long-term idiotype vaccination combined with interleukin-12 (IL-12), or IL-12 and granulocyte macrophage colony-stimulating factor, in early-stage multiple myeloma patients
Lotta Hansson et al.
CLINICAL CANCER RESEARCH (2007)
A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy
Deirdre O'Mahony et al.
CLINICAL CANCER RESEARCH (2007)
Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation
Djordje Atanackovic et al.
BLOOD (2007)
Induction of multiple myeloma-specific cytotoxic T lymphocyte stimulation by dendritic cell pulsing with purified and optimized myeloma cell lysates
Je-Jung Lee et al.
LEUKEMIA & LYMPHOMA (2007)
T lymphocytes redirected against the κ light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells
Juan Vera et al.
BLOOD (2006)
Enhancement of clonogenicity of human multiple myeloma by dendritic cells
Anjli Kukreja et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Lenalidomide in multiple myeloma
Paul G. Richardson et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2006)
Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma
F Garban et al.
BLOOD (2006)
Gastrointestinal graft-versus-host disease in recipients of autologous hematopoietic stem cells: Incidence, risk factors, and outcome
L Holmberg et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2006)
Targeting heat shock proteins for immunotherapy in multiple myeloma: Generation of myeloma-specific CTLs using dendritic cells pulsed with tumor-derived gp96
JF Qian et al.
CLINICAL CANCER RESEARCH (2005)
CD8+T cells specific for cancer germline gene antigens are found in many patients with multiple myeloma, and their frequency correlates with disease burden
O Goodyear et al.
BLOOD (2005)
Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer
AP Rapoport et al.
NATURE MEDICINE (2005)
Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma:: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT
C Crawley et al.
BLOOD (2005)
Activated marrow-infiltrating lymphocytes effectively target plasma cells and their clonogenic precursors
K Noonan et al.
CANCER RESEARCH (2005)
Mechanisms and functional significance of tumour-induced dendritic-cell defects
D Gabrilovich
NATURE REVIEWS IMMUNOLOGY (2004)
Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes
T Hayashi et al.
BLOOD (2003)
Cancer/testis antigens: an expanding family of targets for cancer immunotherapy
MJ Scanlan et al.
IMMUNOLOGICAL REVIEWS (2002)
Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6
M Ratta et al.
BLOOD (2002)
CTLA-4: new insights into its biological function and use in tumor immunotherapy
JG Egen et al.
NATURE IMMUNOLOGY (2002)
Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma
R Bellucci et al.
BLOOD (2002)
Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy
YJ Wen et al.
BLOOD (2002)
Donor lymphocyte infusion enhances remission status in patients with persistent disease after allografting for multiple myeloma
N Kröger et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Molecular cloning of CS1, a navel human natural killer cell receptor belonging to the CD2 subset of the immunoglobulin superfamily
KS Boles et al.
IMMUNOGENETICS (2001)
Share Paper
